Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8407
Nov 19 • 9:54 AM ET Dollar change+0.0159 Percentage change(1.93%)
Index
-
Market Cap
3.72M
Enterprise Value
-12.28M
Income
-12.76M
Sales
1.00M
Book/sh
3.46
Cash/sh
3.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Feb 13, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
3.72
P/B
0.24
P/C
0.23
P/FCF
-
EV/EBITDA
-
EV/Sales
-12.28
Quick Ratio
7.91
Current Ratio
7.91
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-2.93
EPS next Y
-0.73
EPS next Q
-0.14
EPS this Y
60.23%
EPS next Y
30.48%
EPS next 5Y
33.40%
EPS past 3/5Y
75.03% 65.58%
Sales past 3/5Y
- -
EPS Y/Y TTM
-18.90%
Sales Y/Y TTM
-100.00%
EPS Q/Q
-4582.26%
Sales Q/Q
-
Insider Own
11.64%
Insider Trans
0.00%
Inst Own
35.57%
Inst Trans
18.02%
ROA
-48.87%
ROE
-67.70%
ROIC
-82.76%
Gross Margin
84.19%
Oper. Margin
-890.17%
Profit Margin
-1276.30%
SMA20
-45.44%
SMA50
-60.84%
SMA200
-64.22%
Trades
Shs Outstand
4.42M
Shs Float
3.91M
52W High
2.91 -71.11%
52W Low
0.78 7.78%
Volatility
15.84% 11.53%
ATR (14)
0.14
RSI (14)
16.11
Beta
0.01
Rel Volume
0.79
Avg Volume
34.25K
Volume
3,124
Perf Week
-36.79%
Perf Month
-64.07%
Perf Quarter
-68.39%
Perf Half Y
-68.63%
Perf YTD
-57.32%
Perf Year
-56.21%
Perf 3Y
-83.75%
Perf 5Y
-99.83%
Perf 10Y
-99.99%
Prev Close
0.82
Price
0.84
Change %
1.93%
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
PresidentDr. Brian M. Strem Ph.D.
Chief Financial OfficerMs. Melissa Tosca CPA
Executive Vice President of CMC & OperationsDr. Stefan Sperl Ph.D.
Executive VP and Head of Clinical Development & Regulatory AffairsMr. Keith J. Lane M.B.A.